MedDataX Logo

A Basic-clinical Translational Research in Hepatitis B Virus (HBV)-Specific Antigen Peptides and HepG2 Cell Lysate Co-activated Dendritic Cells Combined With Transarterial Chemoembolization (TACE) in HBV-related HCC Treatment (BTRHBVAPHCLCDCCTCHBVHCCT)

NCT ID: NCT03086564

Last Updated: 2020-10-30

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1/PHASE2

Total Enrollment

70 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-05-01

Study Completion Date

2020-10-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The effect of anti-tumor treatment is not satisfying in HBV-related hepatocellular carcinoma (HBV-HCC) for reasons that HBV-HCC carries highly heterogeneous antigens to facilitate cancer cells escaping from immune surveillance and constructs an immunosuppressive microenvironment. Correspondingly, dendritic cells activated by HBV antigen peptides and HepG2 cell protein lysate can efficiently present T cells with antigens of HCC to sensitize their antitumor properties meanwhile cyclophosphamide(CY) can effectively improve the microenvironment of immunity. Therefore, we put forward a new scientific therapy called "Activated Dendritic-cells Combined Cyclophosphamide" (ADCC) combining with TACE for patients with advanced hepatocellular carcinoma to prolong their survival time.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patients who have good compliance complying with the inclusion criteria will be enrolled into our research. The 70 patients will be randomly assigned to experimental group and control group with the ratio of 1:1, one group (control group) will go on receiving the TACE treatment solely; another group (experimental group) after enrollment will receive TACE in the first course.Then 10ml blood is taken for activated dendritic cells culture.CY treatment will be performed on patients in reasonable dose two days before the second TACE.The day when the second TACE performed, these patients will receive activated-dendritic cells simultaneously. 31 days after the first TACE therapy, all patients are determined if they should continue an additional course by monitoring their blood parameters, tumor indicators and imaging examinations. Additionally, we are setting up a treatment course containing 31 days and going to change one course into 93 days after the third course.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hepatocellular Carcinoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

ADCC & TACE

The first course :

Patients in the first day of a clinical course will be performed TACE solely and keep 40ml blood sample as baseline sample for scientific research;in the 17th day, 10ml blood will be taken to culture activated dendritic cells;in 29th day, cyclophosphamide(CY) 250mg/m2 is used through an intravenous drip;in 31th day,patients are going to be performed TACE,1-2\*10\^8 activated dendritic cells are dripped through peripheral vein, 40ml blood sample will be taken for clinical research, simultaneously.

The 31th day in the first course is the same as the first day of the second course, then we come to next therapy course.

31 days are a course of treatment, health conditions of patients who participate in will be monitored closely in the process. After previous 3-courses followed-up period, one course will be changed into 93 days.

Group Type EXPERIMENTAL

ADCC & TACE

Intervention Type BIOLOGICAL

Experimental groups will be given TACE as well as Activated-Dendritic Cells(1-2\*10\^8,intravenous drip),simultaneously.Cyclophosphamide(250mg/cm2,intravenous drip) will be used two days before TACE performed.

TACE

Every course:

In the first day,patients are performed TACE solely and taken 40ml blood as baseline sample for scientific research;in the 29th day,patients are needed to reach hospital to check related indicators. In the 31th day, patients are performed TACE again.

The 31th day is the same as the first day in the second course.

31 days are a course of treatment, health conditions of patients who participate in will be monitored closely in the process. After previous 3-courses followed-up period, one course will be changed into 93 days.

Group Type ACTIVE_COMPARATOR

TACE

Intervention Type PROCEDURE

TACE solely in the first day of a clinical course.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ADCC & TACE

Experimental groups will be given TACE as well as Activated-Dendritic Cells(1-2\*10\^8,intravenous drip),simultaneously.Cyclophosphamide(250mg/cm2,intravenous drip) will be used two days before TACE performed.

Intervention Type BIOLOGICAL

TACE

TACE solely in the first day of a clinical course.

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with history of hepatitis B infection
* Stage B or C in Barcelona Clinic Liver Cancer(BCLC)
* Eastern Cooperative Oncology Group(ECOG) scores \<= 2.(without portal vein involved)
* Patients have been unable to be performed surgery or liver transplant
* Patients are appropriate to be performed TACE
* 18 or over 18 years old
* Patients haven't received radiation therapy or chemotherapy or immunotherapy
* Normal renal function
* Blood routine test:Hb\>=9g/L,white cell count\>=1.5\*10\^9/L,platelet count\>=50\*10\^9
* Liver function: bilirubin\<=50ummol/L,aspartate aminotransferase (AST) or alanine aminotransferase (ALT)\<=5 times the upper limit of normal
* Child-Pugh score\<=9
* Human Chorionic Gonadotropin (HCG) test negative(-) if patients are women of reproductive ages
* Women of reproductive ages promise to contracept until therapy course has been finished for 3 months
* Patients who have signed up informed consents

Exclusion Criteria

* Extrahepatic metastasis of hepatocellular carcinoma
* History of embolism, chemotherapy or radiation
* History of major surgery in last 4 weeks
* History of radiofrequency ablation in last 6 weeks
* Acute infections in last 2 weeks
* Child-Pugh scores\>9
* Patients with hepatic encephalopathy
* Patients with ascites needed drainage
* HCC with portal vein involved
* Patients have history of cancer
* Patients have history of HIV
* Pregnant women
* Patients with severe diseases like cardiac dysfunction
* Patients with mental illness that influence signing informed consents
* HBV infection combined with other types of hepatitis
* Patients with autoimmune diseases
* Immunosuppressant drugs users
* Patients cannot follow our trial principle
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Yuehua Huang

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Yuehua Huang

Director, Provincial Key Laboratory of Liver

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Lubiao Chen, Dr.

Role: STUDY_CHAIR

the third affiliated hospital of sun yet-sen university

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

The Third Affiliated Hospital of Sun Yat-sen University

Guangzhou, Guangdong, China

Site Status

Countries

Review the countries where the study has at least one active or historical site.

China

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

huangyuehuateam

Identifier Type: -

Identifier Source: org_study_id